Janney Montgomery Scott LLC Purchases 1,216 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Janney Montgomery Scott LLC grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 7.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,829 shares of the biopharmaceutical company’s stock after acquiring an additional 1,216 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Regeneron Pharmaceuticals were worth $14,672,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Meyer Handelman Co. increased its holdings in Regeneron Pharmaceuticals by 11.4% during the 3rd quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company’s stock worth $3,485,000 after purchasing an additional 435 shares in the last quarter. Cavalier Investments LLC grew its stake in shares of Regeneron Pharmaceuticals by 88.6% in the 3rd quarter. Cavalier Investments LLC now owns 4,436 shares of the biopharmaceutical company’s stock worth $3,651,000 after acquiring an additional 2,084 shares in the last quarter. Comerica Bank purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $15,929,000. Vestmark Advisory Solutions Inc. lifted its position in shares of Regeneron Pharmaceuticals by 28.1% during the second quarter. Vestmark Advisory Solutions Inc. now owns 575 shares of the biopharmaceutical company’s stock valued at $413,000 after purchasing an additional 126 shares in the last quarter. Finally, Kingswood Wealth Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the second quarter worth about $274,000. 84.15% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $817.30, for a total value of $81,730.00. Following the completion of the sale, the director now directly owns 18,447 shares in the company, valued at approximately $15,076,733.10. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $817.30, for a total transaction of $81,730.00. Following the completion of the sale, the director now owns 18,447 shares of the company’s stock, valued at approximately $15,076,733.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Christopher R. Fenimore sold 1,680 shares of the business’s stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $844.01, for a total transaction of $1,417,936.80. Following the sale, the senior vice president now owns 17,070 shares in the company, valued at approximately $14,407,250.70. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,911 shares of company stock worth $9,831,770. 8.83% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Stock Up 0.8 %

Shares of NASDAQ REGN opened at $946.43 on Friday. The business has a 50-day moving average of $897.46 and a 200-day moving average of $839.17. The firm has a market capitalization of $103.11 billion, a price-to-earnings ratio of 27.24, a PEG ratio of 2.70 and a beta of 0.11. The company has a current ratio of 5.69, a quick ratio of 5.74 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 12 month low of $684.80 and a 12 month high of $973.99.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. During the same period in the previous year, the firm posted $10.96 EPS. The firm’s revenue was up .6% compared to the same quarter last year. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.74 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on REGN. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 5th. TD Cowen lifted their target price on Regeneron Pharmaceuticals from $900.00 to $1,000.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 6th. BMO Capital Markets increased their price target on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research report on Monday. Piper Sandler boosted their target price on shares of Regeneron Pharmaceuticals from $885.00 to $895.00 and gave the company an “overweight” rating in a research note on Friday, November 3rd. Finally, Barclays lifted their price target on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a report on Tuesday, January 23rd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $939.05.

Get Our Latest Research Report on REGN

Regeneron Pharmaceuticals Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Read More

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.